Collegium Pharmaceutical (COLL) Accumulated Expenses (2014 - 2026)

Collegium Pharmaceutical's Accumulated Expenses history runs 13 years deep, the most recent figure standing at $58.1 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 8.2% year-over-year to $58.1 million; the TTM figure through Mar 2026 stood at $58.1 million (up 8.2% YoY), while the FY2025 annual figure was $62.5 million, down 13.39% from the prior year.
• Accumulated Expenses was $58.1 million for Q1 2026 at Collegium Pharmaceutical, down from $62.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $72.1 million in Q4 2024 to a low of $941000.0 in Q3 2023.
• Historically, Accumulated Expenses has averaged $18.5 million across 5 years, with a median of $7.1 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses plunged 94.62% in 2022, then jumped 2963.85% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $1.4 million in 2022, then surged by 906.95% to $14.2 million in 2023, then jumped by 407.99% to $72.1 million in 2024, then slipped by 13.39% to $62.5 million in 2025, then fell by 6.91% to $58.1 million in 2026.
• The last three Accumulated Expenses figures came in at $58.1 million (Q1 2026), $62.5 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.